-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Initiates Coverage On Definium Therapeutics with Outperform Rating, Announces Price Target of $25

Benzinga·02/24/2026 12:13:06
Listen to the news
Wolfe Research analyst Rudy Li initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Outperform rating and announces Price Target of $25.